ArticleBMC cancer2025
Modulating tumor interstitial fluid pressure using ultrasound and microbubble therapy: a preclinical study for enhanced drug delivery in cancer treatment.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- The mechano-immunological landscape in the tumor microenvironment: From mechanical sensing to a new therapeutic paradigm.Materials today. Bio · 2026Review
- Polymeric Nano Drug Delivery Systems for Overcoming Tumor Microenvironment-Mediated Drug Resistance.Pharmaceutics · 2026Review
- Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThe tumor microenvironment (TME) often hinders effective cancer treatment, where elevated interstitial fluid pressure (IFP) acts as a key barrier to drug penetration. This study investigates the distribution of IFP in VX2 tumors and the effect of ultrasound-mediated microbubble (USMB) therapy on reducing IFP to improve drug delivery.
methodsFollowing approval from the Animal Ethics Committee of the South China University of Technology and adhering to NIH animal care guidelines, forty-one healthy female New Zealand White rabbits with VX2 tumors underwent USMB therapy at varying ultrasound pressures (1 MPa, 2 MPa, 3 MPa, and 5 MPa). IFP measurements across different tumor regions were performed pre- and post-treatment using the wick-in-needle (WIN) method to assess IFP variability and distribution. Contrast-enhanced ultrasound (CEUS) was used to evaluate changes in tumor perfusion associated with USMB treatment.
resultsSignificant regional differences in tumor IFP were observed, with the central region (23.79 ± 8.07 mmHg) markedly higher than the peripheral 1/2 (15.58 ± 5.22 mmHg) and peripheral 1/4 regions (8.29 ± 3.47 mmHg). After treatment, 3 MPa and 5 MPa ultrasound pressures significantly reduced IFP in the central region to 18.05 ± 8.1 mmHg and 14.69 ± 4.72 mmHg, respectively. Histological analysis showed that higher pressures caused greater tumor cell and vascular damage, with extensive necrosis and vascular disruption in the central tumor area at 3 MPa and 5 MPa, demonstrating the impact of USMB therapy on the tumor microenvironment.
conclusionUSMB therapy reduces IFP in solid tumors. At 2 MPa, IFP reduction occurs with minimal perfusion change, potentially favoring drug delivery. In contrast, higher pressures (3-5 MPa) also lower IFP but markedly decrease perfusion through vascular disruption, which may hinder drug transport. These findings highlight the need to adjust ultrasound parameters based on regional IFP distribution and to balance IFP reduction with perfusion preservation to optimize treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.